Document:

Amendment No.3 to Product Development and Commercialization Agreement

 Exhibit 10.15 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 AMENDMENT NO. 3 
 to 
 PRODUCT DEVELOPMENT AND 

COMMERCIALIZATION AGREEMENT 
 This Amendment No. 3 (“Amendment No. 3”) to that certain PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT entered into and made effective as of the 22nd day of August, 2006, and as amended by Amendment No. 1
effective as of the 30th day of September, 2007, and by
Amendment No. 2 effective as of the 6th day of
October, 2008 (the “Agreement”), by and between ChemoCentryx, Inc., a Delaware corporation having its principal place of business at 850 Maude Avenue, Mountain View, CA 94043 (“ChemoCentryx”), and Glaxo Group
Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (referred to herein as “GSK”), collectively, the
“Parties”, is hereby entered into by the Parties with an Amendment No. 3 effective date of August 22nd, 2009 (the “Amendment No. 3 Effective Date”). 

WHEREAS, ChemoCentryx has been conducting research under the Agreement during the Research Term to identify Development Candidates for
each of four (4) different Collaboration Targets, pursuant to a Research Plan; 
 WHEREAS, the Research Term is scheduled
to expire on August 22, 2009, and GSK did not exercise its right to extend the Research Term by one (1) year by February 22, 2009, as set forth in Section 3.1.1 of the Agreement; and 

WHEREAS, notwithstanding the expiration of the Research Term on August 22, 2009, and notwithstanding the requirements under
Section 3.1.1 for invoking a Research Term Extension, the Parties desire that ChemoCentryx continue after such expiration to conduct certain limited research activities, and that GSK continue to fund such activities, in each case under the
terms and conditions herein. 
 NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth
below, the Parties do hereby amend the Agreement and otherwise agree as follows: 

1.        Except as amended hereby, the Agreement will remain unchanged and in full force and
effect. The Agreement together with this Amendment No. 3 will be read, taken and construed as one and the same instrument. All terms used in this Amendment No. 3 but not defined herein will have the same meanings set forth for such terms
in the Agreement. 

 2.        In Sections 1.19.2 and 1.19.2(b) of the
Agreement, after “Research Term”, insert “or Additional Research Period”. 

3.        Section 1.119 of the Agreement is hereby amended and restated in its entirety as
follows (newly added text in bold and underlined): 
 1.119    “Research
Program” shall mean the program of research, discovery, characterization, optimization and pre-clinical testing of Collaboration Compounds up until IND Studies to be conducted by ChemoCentryx during the Research Term and for
Collaboration Target ChemR23, during the Additional Research Period, as set forth in Article 3. 

4.        In Sections 2.3 and 5.1.1 of the Agreement, after “Research Term”, insert
“and Additional Research Period”. 
 5.        Section 3.1.2 of the
Agreement is hereby amended and restated in its entirety as follows (newly added text in bold and underlined): 

3.1.2    Clarifications.    The Research Program shall be
conducted by ChemoCentryx for each Collaboration Target throughout the duration of the Research Term and for Collaboration Target ChemR23 throughout the duration of the Additional Research Period unless earlier terminated by a decision
of the JSC. The objective of the Research Program is to identify a Development Candidate and at least two (2) Backup Compounds to each Development Candidate for each Collaboration Target. 

6.        The following new Section 3.1.3 is hereby added to the Agreement: 

3.1.3    Additional Research
Period.    Notwithstanding anything in this Agreement to the contrary, following, the expiration of the Research Term on August 22, 2009, until February 28, 2010 (the “Additional Research
Period”), ChemoCentryx shall continue to conduct research under the Research Plan for Collaboration Target ChemR23 only. Prior to the expiration of the Research Term, as necessary, the JSC shall amend the Research Plan to reflect the research
activities ChemoCentryx will conduct during the Additional Research Period. During the Additional Research Period, ChemoCentryx will have the responsibilities applicable to its activities under the Research Plan with respect to ChemR23 as set forth
in Section 3.3.4. GSK shall provide funding for ChemoCentryx’ activities during the Additional Research Period pursuant to Section 3.11.3. 

7.        Section 3.2.2 of the Agreement is hereby amended and restated in its entirety as
follows (newly added text in bold and underlined): 
 3.2.2    If No Development
Candidate Selected.    For clarity, if no Development Candidate has been selected by the JSC (or by GSK) against a certain Collaboration Target (other than ChemR23) by the end of the Research Term, or
against ChemR23 by the end of the Additional Research Period, ChemoCentryx shall not be required to conduct any activities under any Early Development Program with respect to such Collaboration Target and the Collaboration Compounds directed
against such Collaboration Target shall revert to ChemoCentryx subject to the other terms and conditions of this Agreement; provided, however that if at the end of the Research Term, no Collaboration Compound has been nominated by the

  
 2 

 
JSC as a Development Candidate which targets a given Collaboration Target other than CCR9 or ChemR23, or if at the end of the Additional Research Period, no Collaboration Compound has been
nominated by the .ISC as a Development Candidate against ChemR23, GSK shall have the right (exercisable only once per Collaboration Target), upon the payment of the Development Candidate Selection Milestone set forth in Section 6.4.2,
to nominate at its sole discretion, a Collaboration Compound as a Development Candidate against such Collaboration Target (as well as two (2) additional Collaboration Compounds against such Collaboration Target to be deemed as Back-up Compounds
thereto), such nominated Collaboration Compound to be deemed a Development Candidate (and thus, with its Back-up Compounds, Progressed Compounds) for all purposes under this Agreement, whereupon an Early Development Program for such Development
Candidate for the relevant Collaboration Target shall be prepared and conducted by ChemoCentryx as provided in Section 3.2.1 and in accordance with the relevant provisions of this Agreement. 

8.        The third sentence of Section 3.6.2 of the Agreement is hereby amended and
restated in its entirety as follows (newly added text in bold and underlined): 
 In the event that no proposed Development
Candidate with respect to a given Collaboration Target (other than ChemR23) has been approved by the JSC as described above by the end of the Research Term or, with respect to ChemR23, by the end of the Additional Research
Period, the Parties shall proceed in accordance with Section 3.2.2 with respect to such Collaboration Target. 

9.        The following new Section 3.11.3 is hereby added to the Agreement: 

3.11.3 Funding for Additional Research Period.    GSK will support
ChemoCentryx’ efforts under the Research Plan during the Additional Research Period by paying ChemoCentryx two (2) research funding payments, each in the amount of [***] Dollars ($[***]), as provided in and subject to the adjustment
described in this Section 3.11.3. On or before each of September 1, 2009 and December 1, 2009, ChemoCentryx shall submit to GSK an invoice for such amount, and GSK shall pay each such invoice within thirty (30) days of receipt of
the invoice. Within thirty (30) days after the end of the Additional Research Period, ChemoCentryx shall submit to GSK a statement setting forth the actual FTE costs (based on the number of FTEs that actually worked on the Research Plan during
the Additional Research Period, multiplied by the [***] in effect when such costs were incurred) and other reasonable out-of-pocket expenses incurred by ChemoCentryx in performing the Research Plan during the Additional Research Period (all such
costs and expenses, the “Additional Research Cost”), as supported by written documentation. If the Additional Research Cost is less than [***] Dollars ($[***]) and GSK has paid the invoices described above in this Section 3.11.3, then
ChemoCentryx shall pay GSK an amount equal to the difference between [***] Dollars ($[***]) and the Additional Research Cost, within thirty (30) days after the end of the Additional Research Period. If the Additional Research Cost exceeds [***]
Dollars ($[***]), then no further payments shall be due from GSK to ChemoCentryx under this Section 3.11.3 beyond the invoices described above. 

***    Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 3 

 10.        For the avoidance of doubt, this
Amendment No. 3 shall have no effect on the Research Term, which shall expire on August 22, 2009, or on the time periods in Article 7 of the Agreement that are measured in terms of and/or with reference to the Research Term and/or its
expiration date. 
 11.        The first sentence of Section 9.6 of the Agreement
is hereby amended and restated in its entirety as follows (newly added text in bold and underlined): 
 Neither Party or its
Affiliates shall publish or publicly disclose the results of any of the research and/or development activities conducted under the Research Program or under any Early Development Program, without the prior written consent of the other Party,
except that after the end of the Additional Research Period with respect to ChemR23, and after the end of the Research Term with respect to all other Collaboration Targets, the foregoing shall not apply to
ChemoCentryx for results that do not relate to any Collaboration Compounds, or to GSK for results that relate directly to any of the Product Candidates or Licensed Products. 
 12.        All other provisions of the Agreement will remain unchanged and remain in full force and effect. This Amendment No. 3 may be executed in
counterparts and all such counterparts taken together shall be deemed to constitute one and the same instrument. 
 THE REMAINDER
OF THIS PAGE INTENTIONALLY LEFT BLANK 
 SIGNATURE PAGE FOLLOWS 

  
 4 

 IN WITNESS WHEREOF, each of the Parties has caused this Amendment No. 3 to be
duly executed by its duly authorized representatives as of the Amendment No. 3 Effective Date. 
  

	
	GLAXO GROUP LIMITED
	
	 By: /s/ Paul
Williamson                            

	
	 Name: Paul Williamson

					
		
	 Title:
	 	For and on behalf of Edinburgh Pharmaceutical
		 	 Industries Limited
 Corporate
Director
	 	

	
	
	 CHEMOCENTRYX, INC.

	
	 By: /s/ Thomas J.
Schall                            

	
	 Name: Thomas J. Schall

			
		
	 Title:
	 	President and Chief Executive Officer

  
 5Amendment No.4 to Product Development and Commercialization Agreement

 Exhibit 10.16 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 AMENDMENT NO. 4 
 to 
 PRODUCT DEVELOPMENT AND 

COMMERCIALIZATION AGREEMENT 
 This Amendment No. 4 (“Amendment No. 4”) to that certain PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT entered into and made effective as of the 22” day of August,
2006, and as amended by Amendment No. 1 effective as of the 30th day of September, 2007, by Amendment No. 2 effective as of the 6th day of October 2008, and by Amendment No. 3 effective as of the 22” day of August 2009 (the
“Agreement”) by and between ChemoCentryx, Inc., a Delaware corporation having its principal place of business at 850 Maude Avenue, Mountain View, CA 94043 (“ChemoCentryx”), and Glaxo Group Limited, a company existing under
the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (referred to herein as “GSK”), collectively, the “Parties”, is hereby
entered into by the Parties with an Amendment No. 4 effective date of February 26, 2010 (the “Amendment No. 4 Effective Date”). 
 WHEREAS, the Parties now agree to conduct (i) a preclinical study for the AMD indication for the C5aR Collaboration Target entitled, “Studies for Evaluation of CCX168 in [***]” to support
AMD indication (the “[***] Study”), and (ii) a [***] Toxicology Evaluation of CCX168 (the “Tox Study”) under the Agreement (collectively hereinafter the “C5aR Program Studies”); and 

WHEREAS, the Parties now agree to establish a budget and payment schedule that shall apply to each of the C5aR Program
Studies referenced under this Amendment No. 4, subject to the terms and conditions herein, and to establish or clarify certain other issues with respect to the Agreement; and 

NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties do hereby
amend the Agreement and otherwise agree as follows: 
 1.        Except as amended
hereby, the Agreement is ratified, confirmed and reaffirmed in all respects. The Agreement together with this Amendment No. 4 will be read, taken and construed as one and the same instrument. All terms used in this Amendment No. 4, but not
defined herein, will have the same meaning set forth for that term in the Agreement. 

2.        The C5aR Program Studies are in regards to the Development Candidate CCX168 targeting
the Collaboration Target C5aR and are designed in accordance with Exhibit 1 and Exhibit 2, which are attached hereto and incorporated by reference. Exhibit 1 shall include, and 
  
  
 ***    Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
incorporate by reference, the protocol covering the [***] Study and Exhibit 2 shall include and incorporate by reference the protocol covering the Tox Study (each such protocol, as included in
Exhibit 1 or Exhibit 2, an “Experimental Protocol”). 

3.        Reimbursement of ChemoCentryx Costs. The C5aR Program Studies shall be part of the
Early Development Program for CCX168. Notwithstanding Section 3.2.1 of the Agreement, GSK shall be responsible for the costs and expenses of the C5aR Program Studies as follows: 

(a)        The [***] Study. GSK shall reimburse ChemoCentryx for its
out-of-pocket expenses incurred as a result of the activities relating to the conduct of the [***] Study, which expenses are estimated to be [***] GBP (£[***]) [or USD$ equivalent]. Payment by GSK will be in two separate installments as
follows: (i) approximately £[***] [or USD$ equivalent] upon the completion of the Experimental Protocol for Study 1, and (ii) approximately £[***] [or USD$ equivalent] upon the completion of the Experimental Protocol for Study
lb. Following completion of each of Study 1 and Study lb, ChemoCentryx will submit an invoice to GSK setting forth the actual out-of-pocket expenditures incurred to conduct the Experimental Protocol for Study 1 or Study lb. All invoiced charges
shall be in accordance with the agreed Study 1 and Study lb Experimental Protocol. All payments due under this Amendment No. 4 will be paid by GSK net thirty (30) days upon receipt by GSK of a complete, accurate and audit-worthy invoice.
All invoices provided to GSK shall reference the Agreement and shall be sent electronically to GSK Attn: [***] for processing. For clarity, except as provided below in this Section 3(a), the maximum amount of money to be paid by GSK for
expenses incurred during a calendar year period for the [***] Study shall be capped at [***] GBP (£[***]) [or USD $ equivalent] (the “[***] Study Cap”). If ChemoCentryx anticipates that the total out-of-pocket expenses to conduct the
[***] Study according to the Experimental Protocol will exceed the [***] Study Cap, ChemoCentryx shall promptly notify GSK in writing. GSK shall notify ChemoCentryx within fifteen (15) days of receipt of such notice of GSK’s decision
either to fund or not to fund such excess amount, which decision shall be at GSK’s sole discretion. If GSK decides not to fund such excess amount, ChemoCentryx shall have the right, at its sole discretion, to fund such excess amount. If neither
Party decides to fund such excess amount, ChemoCentryx shall not be obligated to complete the [***] Study according to the Experimental Protocol, and shall have the right to amend the Experimental Protocol for Study 1 or Study lb, upon written
notice to GSK, such that the total out-of-pocket expenses incurred by ChemoCentryx to conduct the [***] Study do not exceed the [***] Study Cap. In no event shall either Party be responsible for any amounts to conduct the [***] Study in excess of
the [***] Study Cap without such Party’s prior written consent. 

(b)        The Tox Study. GSK shall reimburse ChemoCentryx for its out-of-pocket
expenses incurred as a result of the activities relating to the conduct of the Tox Study, which expenses are estimated to be [***] Thousand USD ($[***]). Payment by GSK will be in quarterly installments based upon a calendar year. Following each
calendar quarter during which ChemoCentryx conducts the Tox Study, ChemoCentryx will submit an invoice to GSK setting forth the actual out-of-pocket expenditures incurred to conduct the Tox Study in such calendar quarter and a quarterly budget
update of incurred expenses. All invoiced charges shall be in accordance with the agreed Tox Study Experimental Protocol. All payments due under this Amendment No. 4 will be paid by GSK net thirty (30) days upon receipt by GSK of a
complete, accurate and audit-worthy invoice. All invoices provided to GSK shall reference the Agreement 
  

  
  

2 
  

 ***    Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
and shall be sent electronically to GSK Attn: [***] for processing. For clarity, the maximum amount of money to be paid by GSK for expenses incurred during a calendar year period for the Tox
Study shall be capped at [***] Thousand USD ($[***]) (the “Tox Study Cap”). 

(c)        GSK has the right to terminate funding the [***] Study and/or the Tox
Study at its sole discretion, for any reason, with or without cause, such termination to be effective ninety (90) days after written notice is provided to ChemoCentryx; whereupon, ChemoCentryx has the opportunity (i) to continue funding
the [***] Study and/or the Tox Study, as applicable, independently of GSK, or (ii) to close the [***] Study and/or the Tox Study, as applicable, down. Upon termination of funding of the [***] Study or the Tox Study by GSK and if ChemoCentryx
closes the [***] Study or Tox Study, ChemoCentryx shall take all reasonable efforts to minimize costs and shall proceed in an orderly fashion to terminate any outstanding cancelable commitments and to stop the [***] Study or the Tox Study, as
applicable. All costs to ChemoCentryx associated with termination will be considered reimbursable costs, as well as costs incurred prior to the notice of termination but which have not been reimbursed, and commitments existing at the time the notice
of termination is received which cannot be cancelled. In no event will reimbursement under this Amendment No. 4 exceed the total budgeted amount stated under 3(a), the [***] Study Cap, or 3(b), the Tox Study Cap, above, unless otherwise agreed
to in writing by the Parties. 
 (d)        In the event that
ChemoCentryx, or its successors and assigns, no longer wish to continue the C5aR Program Studies, ChemoCentryx, or its successors and assigns, cannot terminate the C5aR Program Studies without GSK’s prior written consent, not to be unreasonably
withheld; provided that in no event shall ChemoCentryx be obligated to incur expenses to conduct the C5aR Program Studies in excess of the budgeted amounts set forth in Sections 3(a), the [***] Study Cap, and 3(b) the Tox Study Cap. 

4.        For clarification, this Amendment No. 4 applies only to the Early Development
Program associated with the CCX168 compound and the Collaboration Target C5aR, and no other program or compound under the Agreement. All amounts spent by GSK or ChemoCentryx under this Amendment No. 4 do not qualify, in any way, as PoC Trial
expenditures under Section 2.3.6 of the Agreement. 
 5.        All other
provisions of the Agreement will remain unchanged and remain in full force and effect. This Amendment No. 4 may be executed in counterparts and all such counterparts taken together shall be deemed to constitute one and the same instrument.

 THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK 
 SIGNATURE PAGE FOLLOWS 
  

  

***    Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 
  

  
  

3 
  

 

 IN WITNESS WHEREOF, each of the Parties has caused this Amendment No. 4 to be
duly executed by its duly authorized representative as of the Amendment No. 4 Effective Date. 
 GLAXO GROUP LIMITED 

 

			
	 By :
	 	/s/ Paul Williamson                        
                            

			
		
	 Name:
	 	 Paul Williamson

		 	 For and on behalf of

		 	 Edinburgh Pharmaceutical Industries Limited

		
	 Title:
	 	 Corporate Director

 CHEMOCENTRYX, INC. 
  

			
	 By:
	 	/s/ Thomas J. Schall                       
                             
		
	 Name:
	 	 Thomas J. Schall

		
	 Title:
	 	 President and Chief Executive Officer

  
  

4 
  

					
	 ChemoCentryx, Inc.
 CCX168
	  	 	  	 

 EXHIBIT 1 
 Studies for Evaluation of CCX168 in [***] 
 (29 January 2010)

 Experimental protocol for Study 1 
 Rationale: To test the effect of CCX168 on [***] 
 The objectives of
the study include: 
 [***] 
 Experimental plan: [***] 
 Timings and Cost

 [***] 
 Experimental protocol for Study 1b 
 Rationale: To
test the effect of CCX168 on [***] 
 The objectives of the study include: 

[***] 
 Experimental plan: [***] 
 Timings and Cost

 [***] 
 ***    Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

  

					
	 	  	Page 5 of 7	  	26-February-2010

					
	 ChemoCentryx, Inc.
 CCX168
	  	 	  	 

 EXHIBIT 2 
 [***] TOXICOLOGY EVALUATION OF CCX168 
  

					
	 Synthesis of API to support Toxicology studies
	  			
		
	 Starting Materials:
	  	 	$[***]	  
	 Manufacture:
	  	 	$[***]	  
		
	 13-Week Toxicology studies
	  			
		
	 Develop suitable tox formulation for [***]
	  	 	$[***]	  
	 [***]
	  	 	$[***]	  
	 [***]
	  	 	$[***]	  
	 [***]
	  	 	$[***]	  

 ***    Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

					
	 	  	Page 6 of 7	  	26-February-2010

					
	 ChemoCentryx, Inc.
 CCX168
	  	 	  	 

 Exhibit 2: The Quarterly Budget for Tox Study is attached hereto and made a part hereof:

 [***] 
 ***    Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
	 	  	Page 7 of 7	  	26-February-2010

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]